Last reviewed · How we verify

NCT03402399: MRMF01

Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis

Status unknown NA Last updated 5 July 2019
What this trial tests

NA trial testing Molecular analysis in Myelofibrosis, Primary in 222 participants. Status unknown.

Timeline
10 December 2017
Primary endpoint
9 December 2019
9 December 2020

Quick facts

Lead sponsorAssaf-Harofeh Medical Center
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment222
Start date10 December 2017
Primary completion9 December 2019
Estimated completion9 December 2020
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Assaf-Harofeh Medical Center

Who can join

18 and older, any sex, with Myelofibrosis, Primary or Myelofibrosis, Post PV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to determine the rate of HMR mutations in PMF and secondary MF (post PV/ET) subjects, and correlate the rate of mutations with clinical features as known prognostic scores.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Molecular analysis

Trials testing the same drug.

Other recruiting trials for Myelofibrosis, Primary

Currently open trials in the same condition.

Other Assaf-Harofeh Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03402399.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing